The Cell and Gene Therapy Catapult (CGT Catapult) is an independent not-for-profit innovation and technology organisation committed to the advancement of cell and gene therapies.
Viral vector manufacturing capacity is limiting the development of therapies globally. See CGT Catapult's presentation on the current state, barriers, and solutions to challenges in viral vector manufacturing. The presentation slides are available as a PDF to download or view online.
An on-demand webinar for this presentation is available here.
Topics covered in this presentation and the webinar include:
- The current state of viral vector manufacturing and the implications for the wider industry
- Barriers to the process development of viral vector manufacturing
- Next generation analytics for viral vectors including quantity and purity assays, and in-line analytics
- Case study: Higher sensitivity analytics to support AAV process development
